Seroprevalence of hepatitis C viral antibodies in pregnancy in a tertiary health facility in Nigeria

Nigerian Journal of Clinical Practice

Volumn 12, Issue 1, 2009, Pages 65-73

  Onakewhor, J U E ^a   Okonofua, F E ^a  

^a UNIVERSITY OF BENIN   (Nigeria)

Author keywords

HCV; Nigeria; Pregnancy; Seroprevalence; Vertical transmission

Indexed keywords

HEPATITIS C ANTIBODY;

ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; FEMALE; HEPATITIS C; HUMAN; NIGERIA; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL CARE; UNIVERSITY HOSPITAL;

COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HOSPITALS, UNIVERSITY; HUMANS; NIGERIA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; SEROEPIDEMIOLOGIC STUDIES;

EID: 68949088329     PISSN: 11193077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Dabis F, Ekpini ER. AIDS in Africa: HIV1/AIDS and maternai and child health in Africa. Lancet 2002; 359: 2097-104.
2. Centers for Disease Control and Prevention. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination, Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1991; 40(RR-13): l-25.
3. KovacsA, Schluchter M, Easley K, Demmler G, Shearer W, et al. Cytomegalovirus Infection and HIV-I Disease Progression in Infants Born to HIV-lInfected Women. NEJM 1999; 2(341): 77-84.
4. World Health Organization. World Health Organization Report on Infectious Diseases. Removing obstacles to healthy development. WHO 1999; Geneva.
5. Centers for Disease Control and Prevention. 1993 Sexually transmitted diseases treatment guidelines. MMWR 1993; 42 (No. RR-14).
6. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, Report of the U.S. Preventive Services Task Force. Williams and Wilkins: Baltimore, MD., 1989.)
7. SeowHF. Hepatitis B and C in pregnancy. Cur Obstet Gynaecol 1999; 9: 216223.
8. Seminars in Pediatric Infectious Disease 1997; 8: 17-22.
9. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-212.
10. Lauer GM, Walker BD. Hepatitis C Virus Infection NEJM 2001; 345(1): 41-52.
11. Frank C, Mohamed MK, Strickland G T, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-891.
12. Couzigou P, Richard L, Dumas F, Schouler L, Fleury H. Detection of HCV-RNA in saliva of patients with chronic hepatitis C. Gut 1993; 34:Suppl:S59-S60.
13. Abe K, Kuráta T, Shikata T, Sugitani M, Oda T. Experimental transmission of non-A, non-B hepatitis by saliva. J Infect Dis 1987; 155:1078-1079
14. Imarengiaye CO, Enoselease ME, Iribogbe PE, Ehigiegba AE. Risk of transfusiontransmitted hepatitis C virus in a tertiary hospital in Nigeria. Public Health 2006; 120: 274-278.
15. Erhabor O, Ejele O.A, Nwauche CA. The risk of transfusion-acquired hepatitis C infection among blood donors in Port Harcourt: the question of blood safety in Nigeria. Nig. J Clin Pract. 2006; 9(1): 18-21.
16. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, et al The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
17. Mitsui T, Iwano K, Masuko K, Yamazaki C, Okamoto H, et ai. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992; 16: 1109-1114.
18. Hernandez ME, Bruguera M, Puyuelo T, Barrera JM, Sanchez TJM, Rodes J. Risk of needle-stick injuries in the transmission of hepatitis C virus in hospital personnel. J Hepatol 1992; 16: 56-58.
19. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, et al Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch Virol 1998; 143: 2493-2503.
20. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, et al (The International Hepatitis Interventional Therapy Group). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
21. McHutchison JG, Gordon SC, Schiff ER, Shiffman M L, Lee WM, et al(The Hepatitis Interventional Therapy Group).Interferon alfa-2b alone or in combination with ribavirin as initital treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
22. Rustgi V K, Goodman ZD, Ling M, Cort S, Albrecht JK .(The Hepatitis Interventional Therapy Group). Interferon alfa-2b alone or in combination with ribavirin as initital treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492
23. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282: 103-107
24. Okuda M, Hino K, Korenaga M, Yamaguchi Y, Katoh Y, Okita K. Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Hepatology 1999; 29: 217-222.
25. Zignego AL, De Carli M, Monti M, Careccia G, La Villa G, et al. Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected subjects. J Med Virol. 1995; 47:58-64
26. FerayC, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117:619-625.
27. Alfredo A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. The ECC Jury short statement of the first european consensus conference on the treatment of chronic hepatitis b and c in HIV co-infected patients. Journal of Hepatology 2005; 42 (5):615-624.
28. Wyld R, Robertson JR, Brettle RP, Mellor J, Prescott L, Simmonds P. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doublyinfected individuals. J Infect 1997; 35:163-166
29. Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1infected mothers. Women and Infants Transmission Study. J Infect Dis. 1998. June; 177(6): 1480-1488.
30. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual cotransmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991; 115: 764-768.
31. Soto B, Rodrigo L, Garcia-Bengoechea M, Sanchez-Quijano A, Riestra S, Arenas JI, et al. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case - A multicentre study of 423 pairings. J. Intern. Med. 1994; 236: 515-519.
32. Floreani A, Paternoster D, Zappala F, Cusinato R, Bombi G, Grella P, et al. Hepatitis C infection in pregnancy. Br J Obstet Gynecol 1996; 103:325329.
33. Infectious Diseases and Immunization Committee, Canadian Paediatric Society (CPS). Vertical transmission of the hepatitis C virus: Current knowledge and issues. Paediatrics & Child Health 1997; 2(3):227-31
34. Resti M, Azzari C, Mannelli F, Moriondo M, Novembre E, et al.( Tuscany Study Group on Hepatitis C Virus). Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV1. Infection. BMJ 1998; 317:437-441.
35. Offor E, Onakewhor JUE, Okonofua FE. Maternal and Neonatal Seroprevalence of Human Immunodeficiency Virus Antibodies in Benin City, Nigeria. J. Obstet Gynaecol 2000; 20(6): 583-586
36. Onakewhor JUE, Offor E, Okonofua FE. Maternal and Neonatal Seroprevalence of Hepatitis B Surface Antigen (HBsAg) in Benin City, Nigeria. J. Obstet. Gynaccol. 2001; 21(6): 583-586.
37. Onakewhor JUE, Offor E, Okonofua FE. Seroprevalence of Maternal and Neonatal antibodies to Human Immunodeficiency and Hepatitis B Viruses in Benin City, Nigeria. J. Med Biomed Res 2002; 1(1)32-38.
38. Njouom R, Pasquier C, Ayouba A, Tejiokem M C, Vessiere A, Mfoupouendoun J, et al. Low Risk of Mother-To-Child Transmission of Hepatitis C Virus in Yaounde, Cameroon: The Anrs 1262 Study. Am. J. Trop. Med. Hyg. 2005; 73(2): 460-466
39. Reinus JF, Leikin EL, Alter HJ, Cheung L, Shindo M, Jett B, et al. Failure to detect vertical transmission of hepatitis C virus. Ann Intern Med 1992; 117:881-6.
40. Bohman VR, Stettler RW, Little BB, Wendel GD, Sutor L J, Cunningham FG. Seroprevalence and risk factors for hepatitis C virus antibody in pregnancy. Obstet Gynecol 1992; 80:609-13.
41. Zanetti AR, Tanzi E, Paccagnini S, Principi N, Pizzocolo G, Caccamo ML, et al. Motherto-infant transmission of hepatitis C virus. Lancet 1995; 345: 289-291
42. Pipan C, Amici S, Astori G, Ceci G, Botta G. Vertical transmission of hepatitis C virus in low-risk pregnant women. Eur J Clin Microbiol Infect Dis 1996; 15: 116120.
43. Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994; 330:744-750
44. Matsubara T, Sumazaki R, Takita H. Mother-to-infant transmission of hepatitis C virus: A prospective study. Eur J Pediatr 1995; 154: 973-978
45. Ni Y-H, Lin H-L, Chen PJ, Hsu HY, Chen DS, Chang MH. Temporal profile of hepatitis C virus antibody and genome in infants born to mothers infected with hepatitis C virus but without human immunodeficiency virus coinfection. J Hepatol 1994; 20:641-645
46. Roudot-Thoraval F, Pawlotsky J, Thiers V, Deforges L, Girollet P, Guillot F, et al. Lack of mother-to-infant transmission of hepatitis C virus in human immunodeficiency virusseronegative women: a prospective study with hepatitis C virus RNA testing. Hepatology 1993; 17: 772777.
47. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495
48. Dienstag J.L. Sexual and Perinatal Spread of Hepatitis C Virus Infection. Paper written as part of a National Institute of Health Consensus Conference on Hepatitis C, held March 24-26, 1997 in Bethesda Maryland. The Hepatitis Information Network, 1997.
49. Takaki A, Wiese M, Maertens G, Depla E, Seifert U,Liebetrau, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6:578-582.
50. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology 1997; 26:Suppl 1:2S-10S.
51. Persico M, Perrotta S, Persico E, Terracciano L, Folgori A, Ruggeri L, et al. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. Journal of Viral Hepatitis 2006; 13:290-296.
52. Kuroki T, Nishiguchi S, Fukuda K, Nakajima S, Shiomi S, Murata R, et al. Transmission of hepatitis C virus from mothers with chronic hepatitis C without human immunodeficiency virus. J Infect Dis 1992; 166:1192-1193.
53. Paccagnini S, Principi N, Massironi E, Tanzi E, Romano L, Muggiasca ML, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J 1995; 14:195-199.
54. Raffaele Bruno, Paolo Sacchi, and Gaetano Filice. Hepatitis C virus RNA dynamics during antiretroviral therapy. Blood 2001; 97(10):3318-3319.
55. Yokozaki S, Takamatsu J, Nakano Y, Katano H, Toyoda K, Hayashi K, et al. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000; 96(13):4293-4299.
56. Heathcote EJ, Shiffman ML, Cooksley WGE, Dusheiko G M, Lee SS, Balart L et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680.
57. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC,Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International hepatitis interventional therapy group. N Engl J Med 1998; 339: 1493-1499.
58. International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, consensus statement. J Hepatol 1999; 30:956961.
59. Lemon SM, David LT. Vaccines to Prevent Viral Hepatitis. N Engl J Med 1997; 3(336): 196-204.